Taking both rifampin and isoniazid is crucial for effective tuberculosis treatment, as their combined action targets different aspects of bacterial growth, reducing the risk of drug resistance.
It is crucial for a client with active pulmonary tuberculosis (TB), prescribed rifampin and isoniazid orally on a daily basis, to take both medications due to the distinct mechanisms of action and the potential development of drug resistance. Rifampin and isoniazid work synergistically to combat Mycobacterium tuberculosis, the causative agent of TB.
Rifampin inhibits RNA synthesis in bacteria, including M. tuberculosis, preventing the formation of essential proteins. Isoniazid, on the other hand, interferes with the synthesis of mycolic acids, critical components of the bacterial cell wall. Together, these medications target different aspects of the bacteria's life cycle, increasing the effectiveness of the treatment and reducing the likelihood of resistance development.
Completing the full course of both medications is essential to eradicate all susceptible bacteria and prevent the emergence of drug-resistant strains. TB treatment requires a prolonged duration to ensure that dormant bacteria are also eliminated. Failure to complete the full course or taking only one of the prescribed medications may lead to the survival of drug-resistant strains, making future treatment more challenging.
The question probable may be:
Why is it important for a client with active pulmonary tuberculosis, prescribed rifampin and isoniazid PO daily, to take two medications?